Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses. The firm has a rich history that can be traced all the way back to 1935. Cipla was founded by Dr Khwaja Abdul Hamied. Initially, the company was called The Chemical, Industrial & Pharmaceutical Laboratories. The firm has been set up in order to make India self-reliant in the field of healthcare. In 1952, the pharmaceutical company opened its first research division to develop medicines. In the 1960s, Cipla Limited got into the business of manufacturing Active Pharmaceutical Ingredients (APIs). This was a significant step towards the bulk production of medicine in the country. In 1978, Cipla started manufacturing of Metered-Dose Inhaler (MDI). 1984 was the year when the company name was changed from The Chemical, Industrial & Pharmaceutical Laboratories to Cipla Limited. In the following year, Cipla received approval from United States Food and Drug Administration (USFDA) to manufacture medicines in bulk for HIV. In 1994, Cipla introduced Deferiprone which was stated to be the world’s first oral iron chelator for the treatment of thalassemia. In 1996, Cipla introduced the first transparent dry powder inhaler. At the end of the 20th century, Cipla began a strategic partnership with multinational pharmaceutical company Ranbaxy Laboratories. 2013 was a significant year for Cipla as it purchased the South African firm Cipla-Medpro. This company had previously been a joint venture between Cipla and Medpro Pharmaceuticals. In 2013, Cipla got its hands on Medpro South Africa with a 100 per cent stake acquisition. 2015 was the year when Cipla acquired US generic drug makers InvaGen and Exelan. In 2016, Cipla sold its minority stake in US-based Chase Pharma. In 2020, Cipla in order to strengthen its own health segment acquired four brands from pharmaceutical company Wanbury. In 2022, Cipla Health, the consumer healthcare subsidiary of Cipla Ltd purchased the nutritional supplement brand Endura Mass from Medinnbelle Herbalcare.
Products and services
Cipla is among India’s biggest manufacturers of generic drugs for various ailments across therapeutic areas. The areas covered by Cipla include respiratory, cardiovascular, anti-infectives, oncology and central nervous system disorders among others. Cipla also produces APIs used in the manufacture of various drugs. Cipla has state-of-the-art research facilities for API process development at three locations in India. Cipla also has an Over the Counter (OTC) business wherein it sells multiple products such as Cofsils, Ciphands, Nicotex, Omnigel and Maxirich.
Shares of Cipla are listed on BSE, NSE, Madras Stock Exchange, Calcutta Stock Exchange, etc. The company is a part of multiple indices like Nifty 50, Nifty 500, S&P BSE Sensex 50 etc.
DATA SOURCES: Corporate data, historical price & volume data published on this website have been sourced from CMOTS Internet Technologies Pvt. Ltd. BSE Quotes and NSE Quotes have been sourced from BSE Limited and NSE Data & Analytics Limited, respectively. All timestamps reflected here are in IST (Indian Standard Time). Stock Analysis section has been sourced from the mentioned partners.
DISCLAIMER: Any and all content on this website, including the tools/ analysis, is provided to you only for convenience and on an “as-is, as-available” basis without representation and warranties of any kind. The content and any output of such tools/ analysis is for informational purposes only and should not be relied upon or construed as investment advice or guarantee for any specific performance/ returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.
Copyright©2023 Living Media India Limited. For reprint rights: Syndications Today